Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CORRESPONDENCE

Psychedelic drugs: more emphasis on safety issues

  1. Florian Naudet

    1. University of Rennes, Rennes, France.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Eiko I. Fried

    1. Leiden University, Leiden, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Lisa Cosgrove

    1. University of Massachusetts Boston, Boston, Massachusetts, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Erick Turner

    1. Oregon Health & Science University, Portland, Oregon, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Alain Braillon

    1. Amiens, France.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Ioana A. Cristea

    1. University of Padua, Padua, Italy.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Psychedelic drugs have safety issues that are linked with effects such as hallucinations, paranoia and mood changes. In our view, your editorially independent articles on these drugs — sponsored by the biotechnology firm Atai Life Sciences — should have given more attention to such concerns to avoid serving an industry-friendly narrative that could do more harm than good (see www.nature.com/collections/edcbibiadj).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 611, 449 (2022)

doi: https://doi.org/10.1038/d41586-022-03680-x

Competing Interests

F.N., L.C., E.T., A.B. and I.A.C. are among those on the Lown List of industry independent experts. E.T. is a former FDA reviewer.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links